Received Jul 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLUX | INFLUENZA (SEASONAL) (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | — |
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 2 | UNK | — |
arm was warmer; received the second dose 1 month ago; This non-serious case was reported by a consumer via call center representative and described the occurrence of skin warm in a 67-year-old male patient who received Herpes zoster (Shingles vaccine) for prophylaxis. Co-suspect products included Influenza vaccine for prophylaxis. Previously administered products included Shingrix (received the first dose of shingrix in 2019). Concurrent medical conditions included diabetes (Diabetes). In MAY-2025, the patient received the 2nd dose of Shingles vaccine. On an unknown date, the patient received Influenza vaccine. In MAY-2025, an unknown time after receiving Shingles vaccine and Influenza vaccine, the patient experienced drug dose administration interval too long (Verbatim: received the second dose 1 month ago). On an unknown date, the patient experienced skin warm (Verbatim: arm was warmer). The outcome of the skin warm was unknown and the outcome of the drug dose administration interval too long was not applicable. It was unknown if the reporter considered the skin warm to be related to Shingles vaccine and Influenza vaccine. It was unknown if the company considered the skin warm to be related to Shingles vaccine and Influenza vaccine. Additional Information: GSK Receipt Date: 30-JUN-2025 The patient's arm was warmer for the second shot of Shingrix than when he got the flu vaccine. The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccination schedule. This case was linked with US2025AMR083726, reported by same reporter for different patient.; Sender's Comments: US-GSK-US2025AMR083726:husband case
Diabetes (Diabetes)